MannKind
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.About MNKD
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.
CEOMichael E. Castagna
CEOMichael E. Castagna
Employees414
Employees414
HeadquartersDanbury, Connecticut
HeadquartersDanbury, Connecticut
Founded1991
Founded1991
Employees414
Employees414
MNKD Key Statistics
Market cap1.19B
Market cap1.19B
Price-Earnings ratio-95.02
Price-Earnings ratio-95.02
Dividend yield—
Dividend yield—
Average volume1.91M
Average volume1.91M
High today$4.64
High today$4.64
Low today$4.35
Low today$4.35
Open price$4.45
Open price$4.45
Volume8.40K
Volume8.40K
52 Week high$5.75
52 Week high$5.75
52 Week low$3.17
52 Week low$3.17
MNKD News
Simply Wall St 3d
Analysts Expect MannKind Corporation To Breakeven Soon - Simply Wall StWe feel now is a pretty good time to analyse MannKind Corporation's ( ) business as it appears the company may be on the cusp of a considerable accomplishment....
TipRanks 6d
MannKind to proceed with Phase 1 Nintedanib Dpi (Mnkd-201) studyMannKind announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic p...